{"id":66616,"date":"2026-05-28T22:05:48","date_gmt":"2026-05-28T14:05:48","guid":{"rendered":"https:\/\/flcube.com\/?p=66616"},"modified":"2026-05-28T22:05:49","modified_gmt":"2026-05-28T14:05:49","slug":"dizal-pharmaceuticals-zegfrovy-receives-priority-review-for-first-line-egfr-exon20ins-nsclc-phase-iii-wu-kong28-data-shows-significant-pfs-benefit-over-chemotherapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66616","title":{"rendered":"Dizal Pharmaceutical&#8217;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Dizal Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>) announced that China&#8217;s <strong>Center for Drug Evaluation (CDE)<\/strong> has accepted for review and granted <strong>priority review status<\/strong> to its supplemental indication filing for <strong>Zegfrovy (sunvozertinib)<\/strong> as a first-line treatment for <strong>locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> harboring <strong>epidermal growth factor receptor (EGFR) exon 20 insertion mutations<\/strong>. The filing is supported by positive results from the international Phase III <strong>WU-KONG28<\/strong> confirmatory study.<\/p>\n\n\n\n<h2 id=\"h-regulatory-filing-summary\" class=\"wp-block-heading\">Regulatory Filing Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Dizal Pharmaceutical Co., Ltd. (SHA: 688192)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Zegfrovy (sunvozertinib) \u2013 oral, irreversible, highly selective EGFR TKI<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>Center for Drug Evaluation (CDE), China<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment of EGFR exon20ins NSCLC<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Accepted with priority review designation<\/td><\/tr><tr><td><strong>Supporting Trial<\/strong><\/td><td>Phase III WU-KONG28 international multicenter study<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-free survival (PFS) vs. platinum-based doublet chemotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-molecular-profile-amp-clinical-differentiation\" class=\"wp-block-heading\">Molecular Profile &amp; Clinical Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Oral, irreversible, highly selective EGFR tyrosine kinase inhibitor (TKI)<\/li>\n\n\n\n<li><strong>Target Spectrum:<\/strong> Multiple EGFR mutation subtypes, with specific activity against exon 20 insertion mutations<\/li>\n\n\n\n<li><strong>Current Approvals:<\/strong><\/li>\n\n\n\n<li><strong>China:<\/strong> Second-line and later-line treatment for EGFR exon20ins NSCLC<\/li>\n\n\n\n<li><strong>United States:<\/strong> Later-line treatment for EGFR exon20ins NSCLC<\/li>\n\n\n\n<li><strong>Therapeutic Advance:<\/strong> Potential expansion to first-line setting represents significant clinical advancement<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral dosing regimen enabling outpatient treatment<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-phase-iii-wu-kong28-trial-results\" class=\"wp-block-heading\">Phase III WU-KONG28 Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Design Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Type<\/strong><\/td><td>Open-label, randomized, controlled, international multicenter Phase III<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>First-line EGFR exon20ins NSCLC<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Platinum-based doublet chemotherapy (standard of care)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-free survival (PFS)<\/td><\/tr><tr><td><strong>Key Result<\/strong><\/td><td>Statistically significant and clinically meaningful PFS improvement with sunvozertinib<\/td><\/tr><tr><td><strong>Trial Status<\/strong><\/td><td>Primary endpoint met, supporting regulatory filing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The WU-KONG28 trial represents the first Phase III study to demonstrate superior efficacy of a targeted EGFR TKI over chemotherapy in the first-line EGFR exon20ins NSCLC setting.<\/p>\n\n\n\n<h2 id=\"h-unmet-medical-need-addressed\" class=\"wp-block-heading\">Unmet Medical Need Addressed<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Clinical Challenge<\/th><th>Zegfrovy Solution<\/th><\/tr><\/thead><tbody><tr><td><strong>Limited First-Line Options<\/strong><\/td><td>Targeted therapy specifically designed for EGFR exon20ins mutations<\/td><\/tr><tr><td><strong>Chemotherapy Toxicity<\/strong><\/td><td>Oral targeted therapy with potentially improved safety profile<\/td><\/tr><tr><td><strong>Poor Outcomes with Standard Care<\/strong><\/td><td>Significant PFS benefit demonstrated in Phase III trial<\/td><\/tr><tr><td><strong>Mutation-Specific Treatment Gap<\/strong><\/td><td>Highly selective inhibition addresses unique biology of exon20ins mutations<\/td><\/tr><tr><td><strong>Treatment Sequencing<\/strong><\/td><td>Establishes foundation for optimal treatment pathway in EGFR exon20ins NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">EGFR exon20 insertion mutations represent approximately 4-10% of all EGFR-mutated NSCLC cases and have historically been resistant to first-generation EGFR TKIs.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-market-impact\" class=\"wp-block-heading\">Competitive Landscape &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Line Opportunity:<\/strong> Addresses substantial unmet need in previously untreated EGFR exon20ins NSCLC patients<\/li>\n\n\n\n<li><strong>Regulatory Advantage:<\/strong> Priority review status accelerates potential approval timeline in China<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Building on existing approvals in China and U.S. for later-line indications<\/li>\n\n\n\n<li><strong>Market Differentiation:<\/strong> Only EGFR TKI with Phase III data demonstrating first-line superiority over chemotherapy<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Premium positioning justified by clinical benefit and targeted mechanism<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-dizal\" class=\"wp-block-heading\">Strategic Significance for Dizal<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> Extends Zegfrovy&#8217;s market opportunity from later-line to first-line setting<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Phase III success reinforces Dizal&#8217;s oncology development capabilities<\/li>\n\n\n\n<li><strong>Revenue Growth:<\/strong> First-line indication significantly expands addressable patient population<\/li>\n\n\n\n<li><strong>Global Recognition:<\/strong> International trial design supports potential regulatory submissions in additional markets<\/li>\n\n\n\n<li><strong>Innovation Leadership:<\/strong> Positions Dizal as leader in addressing challenging EGFR mutation subtypes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Dizal Pharmaceutical&#8217;s Zegfrovy regulatory prospects, including CDE review timelines, potential approval outcomes, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive developments, market adoption challenges, and evolving treatment guidelines for EGFR exon20ins NSCLC.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China&#8217;s Center for Drug Evaluation (CDE) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66618,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[191,80,981,33],"class_list":["post-66616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-dizal-pharmaceutical","tag-priority-reviews","tag-sha-688192","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical&#039;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China&#039;s Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66616\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical&#039;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China&#039;s Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66616\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T14:05:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T14:05:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical&#8217;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy\",\"datePublished\":\"2026-05-28T14:05:48+00:00\",\"dateModified\":\"2026-05-28T14:05:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616\"},\"wordCount\":574,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2803.webp\",\"keywords\":[\"Dizal Pharmaceutical\",\"Priority reviews\",\"SHA: 688192\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66616#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66616\",\"name\":\"Dizal Pharmaceutical's Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2803.webp\",\"datePublished\":\"2026-05-28T14:05:48+00:00\",\"dateModified\":\"2026-05-28T14:05:49+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China's Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66616\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal Pharmaceutical's Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66616#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical&#8217;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical's Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China's Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66616","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical's Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China's Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.","og_url":"https:\/\/flcube.com\/?p=66616","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T14:05:48+00:00","article_modified_time":"2026-05-28T14:05:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66616#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66616"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical&#8217;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy","datePublished":"2026-05-28T14:05:48+00:00","dateModified":"2026-05-28T14:05:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66616"},"wordCount":574,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66616#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp","keywords":["Dizal Pharmaceutical","Priority reviews","SHA: 688192","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66616#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66616","url":"https:\/\/flcube.com\/?p=66616","name":"Dizal Pharmaceutical's Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66616#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66616#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp","datePublished":"2026-05-28T14:05:48+00:00","dateModified":"2026-05-28T14:05:49+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China's Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66616#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66616"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66616#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp","width":1080,"height":608,"caption":"Dizal Pharmaceutical's Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66616#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical&#8217;s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC \u2013 Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66616"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66616\/revisions"}],"predecessor-version":[{"id":66619,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66616\/revisions\/66619"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66618"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}